Literature DB >> 6576846

Chronic liver disease in children with leukemia in long-term remission.

A Locasciulli, G M Vergani, C Uderzo, G Jean, M Cattaneo, D Vergani, B Portmann, G Masera.   

Abstract

Liver disease during chemotherapy and after its completion was studied in 103 leukemic children in long-term remission. Seventy developed chronic liver disease during therapy; 22 out of 56 with adequate follow-up showed persisting abnormality or deterioration of liver function after stopping therapy. In 38 studied prospectively, biopsies were obtained at treatment withdrawal. Five showed chronic lobular, 17 chronic persistent, 9 chronic active hepatitis whereas 7 had minimal changes. These children had transiently detectable serum hepatitis-B virus (HBV) markers during (44.4%), at completion of (7.8%) and subsequent to (48.3%) chemotherapy. Serum HBV markers correlated significantly with both severity of histologic changes (P less than 0.05) and persistent biochemical abnormalities for over 6 months after treatment suspension (P less than 0.001). No direct relationship was found between drug administration and liver damage. The data from the study suggest that in leukemic children viral infections contribute to chronic liver damage, which can jeopardize the long-term prognosis of acute leukemia.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6576846     DOI: 10.1002/1097-0142(19830915)52:6<1080::aid-cncr2820520625>3.0.co;2-k

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  5 in total

Review 1.  Treating cancer patients. Practical monitoring and management of therapy-related complications.

Authors:  M Brigden; M McKenzie
Journal:  Can Fam Physician       Date:  2000-11       Impact factor: 3.275

2.  Hepatic late adverse effects after antineoplastic treatment for childhood cancer.

Authors:  Renée L Mulder; Dorine Bresters; Malon Van den Hof; Bart Gp Koot; Sharon M Castellino; Yoon Kong K Loke; Piet N Post; Aleida Postma; László P Szőnyi; Gill A Levitt; Edit Bardi; Roderick Skinner; Elvira C van Dalen
Journal:  Cochrane Database Syst Rev       Date:  2019-04-15

3.  Association of hepatitis C virus infection with chronic liver disease in paediatric cancer patients.

Authors:  F M Fink; S Höcker-Schulz; W Mor; E Puchhammer-Stöckl; H Hofmann; A Zoubek; J Pawlowsky; P Höcker; H Gadner
Journal:  Eur J Pediatr       Date:  1993-06       Impact factor: 3.183

4.  Treatment for hepatitis C virus-induced portal hypertension in leukemic children.

Authors:  Rasha El-Ashry; Hala Abdel Malek; Essam A Desoky Ghayaty; Ahmed A El-Gendy; Ahmad Darwish; Youssef Al-Tonbary
Journal:  Med Oncol       Date:  2013-04-04       Impact factor: 3.064

5.  Interferon for chronic hepatitis C in patients cured of malignancy.

Authors:  S Cesaro; F Rossetti; L De Moliner; C Crivellaro; L Zanesco; F Bortolotti
Journal:  Eur J Pediatr       Date:  1994-09       Impact factor: 3.183

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.